The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

Belgian pharmaceutical company UCB says it plans to invest $5bn in a US factory to avoid President Trump’s tariffs on the EU.

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Belgium-based drugmaker UCB plans to invest $5 ...

UCB, a global biopharmaceutical company, announced plans for a significant investment in a new, state-of-the-art drug ...

UCB already has an R&D base in Slough ... including a new global headquarters and lab in White City, London. Oxford BioMedica, Cobra Biologics and Roslin CT are planning investments of £19 ...

UCB , a Belgian biopharmaceutical firm, ... The logo of Belgian drug, chemical, and plastics group UCB is seen at the entrance of the company's headquarters in Brussels March 2, 2010.

UCB benefits from its geographic diversity, as the company sells drugs in the United States (representing 52% of 2023 sales), Europe (26% of 2023 sales), and Japan (22 of 2023 sales).